1. Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients
- Author
-
Gardin, Antoine, Castelle, Martin, Pichard, Samia, Cano, Aline, Chabrol, Brigitte, Piarroux, Julie, Roubertie, Agathe, Nadjar, Yann, Guemann, Anne-Sophie, Tardieu, Marine, Lacombe, Didier, Robert, Matthieu P., Caillaud, Catherine, Froissart, Roseline, Leboeuf, Virginie, Barbier, Valérie, Bouchereau, Juliette, Schiff, Manuel, Fauroux, Brigitte, Thierry, Briac, Luscan, Romain, James, Syril, de Saint-Denis, Timothée, Pannier, Stéphanie, Gitiaux, Cyril, Vergnaud, Estelle, Boddaert, Nathalie, Lascourreges, Claire, Lemoine, Michel, Bonnet, Damien, Blanche, Stéphane, Dalle, Jean-Hugues, Neven, Bénédicte, de Lonlay, Pascale, and Brassier, Anaïs
- Abstract
Mucopolysaccharidosis type I-H (MPS I-H) is a rare lysosomal storage disorder caused by α-L-Iduronidase deficiency. Early haematopoietic stem cell transplantation (HSCT) is the sole available therapeutic option to preserve neurocognitive functions. We report long-term follow-up (median 9 years, interquartile range 8–16.5) for 51 MPS I-H patients who underwent HSCT between 1986 and 2018 in France. 4 patients died from complications of HSCT and one from disease progression. Complete chimerism and normal α-L-Iduronidase activity were obtained in 84% and 71% of patients respectively. No difference of outcomes was observed between bone marrow and cord blood stem cell sources. All patients acquired independent walking and 91% and 78% acquired intelligible language or reading and writing. Intelligence Quotient evaluation (n= 23) showed that 69% had IQ ≥ 70 at last follow-up. 58% of patients had normal or remedial schooling and 62% of the 13 adults had good socio-professional insertion. Skeletal dysplasia as well as vision and hearing impairments progressed despite HSCT, with significant disability. These results provide a long-term assessment of HSCT efficacy in MPS I-H and could be useful in the evaluation of novel promising treatments such as gene therapy.
- Published
- 2023
- Full Text
- View/download PDF